Pet Biomarkers Market Size and Overview
The global Pet Biomarkers market is estimated at approximately US$ 1.7 billion in 2025 and is projected to reach approximately US$ 3.8 billion by 2035, expanding at a CAGR of about 8.4% during 2026-2035. The market covers protein, genetic, metabolic, cellular and multi-omics biomarkers used for screening, diagnosis, prognosis, treatment selection and disease monitoring in companion animals.
Commercial adoption is strongest where biomarkers directly change clinical decisions. Renal markers such as SDMA, cardiac biomarkers such as NT-proBNP and troponin, inflammatory markers such as CRP, endocrine markers and disease-specific oncology assays are increasingly embedded in veterinary workflows. The next phase of growth will be driven by multiplex panels, liquid biopsy, genomics, proteomics and longitudinal biomarker tracking.
North America remains the largest regional market because of high companion-animal healthcare spending, reference-laboratory depth and rapid adoption of specialty testing. Europe has strong laboratory and academic networks, while Asia-Pacific is expected to grow fastest as specialty veterinary care, pet insurance, molecular diagnostics and premium pet health spending expand.
Pet Biomarkers Market Key Takeaways
- Protein biomarkers remain the largest category because they are already embedded in routine chemistry, cardiac, renal, inflammatory and endocrine testing.
- Renal disease is a major commercial anchor, with SDMA and related markers expanding earlier-stage chronic kidney disease detection and longitudinal monitoring.
- Oncology biomarkers are expected to be among the fastest-growing areas as liquid biopsy, mutation testing and multi-cancer detection move into companion-animal practice.
- Reference laboratories remain central for complex biomarker testing, while point-of-care platforms are expanding access to high-frequency markers.
- Dogs represent the largest animal segment because of higher diagnostic intensity, oncology testing and chronic-disease management.
- Genomics, proteomics and AI-assisted interpretation are increasing biomarker discovery and enabling composite risk scores rather than single-analyte testing.
- Clinical validation, standardized cutoffs and evidence that a biomarker changes treatment remain the main barriers to commercialization.
Pet Biomarkers Industry Trends and Strategic Insights
- Single-analyte testing is giving way to panels that combine renal, inflammatory, cardiac, endocrine and oncology markers with clinical history.
- Liquid biopsy and tumor-derived molecular markers are creating new opportunities in earlier cancer detection, recurrence monitoring and treatment selection.
- Proteomics and metabolomics are expanding biomarker discovery for chronic and multifactorial diseases where traditional chemistry lacks specificity.
- Reference laboratories are integrating biomarker results into longitudinal patient records and specialist interpretation services.
- Point-of-care platforms are adding validated biomarkers to routine workflows, shortening time to treatment decisions.
- Veterinary pharmaceutical companies are increasingly using biomarkers in clinical development, patient stratification and companion-diagnostic strategies.
Pet Biomarkers Market Scope
| Metrics | Details |
| 2025 Market Size | Approx. US$ 1.7 Billion |
| 2035 Projected Market Size | Approx. US$ 3.8 Billion |
| CAGR (2026-2035) | Approx. 8.4% |
| Largest Market | North America |
| Fastest Growing Market | Asia-Pacific |
| By Biomarker Type | Protein Biomarkers, Genetic & Genomic Biomarkers, Metabolic Biomarkers, Cellular & Hematological Biomarkers, Multi-Omics & Composite Panels |
| By Detection Technology | Immunoassay, Clinical Chemistry, PCR & Molecular Diagnostics, Next-Generation Sequencing, Mass Spectrometry & Proteomics, Flow Cytometry, Biosensors, Digital & AI Interpretation |
| By Animal Type | Dogs, Cats, Horses, Other Companion Animals |
| By Disease Area | Renal Disease, Oncology, Cardiac Disease, Endocrine & Metabolic Disorders, Inflammatory & Immune-Mediated Disorders, Gastrointestinal & Pancreatic Disorders, Infectious Disease, Other Disorders |
| By Sample Type | Blood & Serum/Plasma, Urine, Fecal Samples, Tissue, Cytology & Biopsy, Swabs & Other Samples |
| By Application | Early Detection & Screening, Diagnosis & Differential Diagnosis, Prognosis & Risk Stratification, Treatment Selection & Response Monitoring, Research & Companion Diagnostics |
| By End User | Veterinary Hospitals & Clinics, Reference Laboratories, Academic & Research Institutes, Home/Remote Veterinary Care, Other End Users |
| By Distribution Channel | Direct Sales, Veterinary Distributors, Reference-Lab Networks, Online & Digital Ordering, Others |
| Report Insights Covered | Competitive Landscape, Company Profiles, Market Size, Share, Growth, Ecosystem and Country-Level Opportunity |
Why does this report matter in 2026?
The year 2026 is important for pet biomarkers because established markers are moving deeper into routine care while emerging oncology, proteomic and genomic tests are transitioning from research into commercial veterinary workflows. IDEXX has continued to expand SDMA integration and cancer-testing initiatives, strengthening the role of biomarker-led screening within everyday companion-animal diagnostics.
At the same time, AI and multi-omics tools are shortening biomarker discovery cycles and improving interpretation. For investors and suppliers, the key question is shifting from whether biomarkers can be measured to whether they deliver reproducible clinical utility, fit existing workflows and support recurring testing. This report separates validated revenue pools from earlier-stage technologies and maps the companies, laboratories and platforms positioned to commercialize them.
Pet Biomarkers Market White Space & Investment Opportunities
- Multi-cancer early detection and liquid-biopsy panels for dogs and cats.
- Composite kidney-disease risk scores combining SDMA, creatinine, urine markers and clinical data.
- Cardiac biomarker panels for earlier screening of breed-specific and age-related disease.
- Proteomic and metabolomic biomarker discovery platforms for chronic inflammatory and gastrointestinal disorders.
- Companion diagnostics supporting targeted veterinary oncology and immunomodulatory therapies.
- At-home or minimally invasive sample collection linked to centralized biomarker testing and longitudinal monitoring.
Pet Biomarkers Future Market Transformation
The market will increasingly move toward biomarker-centered care pathways in which screening, diagnosis, prognosis and treatment monitoring use linked molecular and clinical data. Composite panels will combine conventional chemistry with protein, genetic and metabolomic markers, while AI will help interpret longitudinal changes rather than isolated values. Reference laboratories and in-clinic systems will remain complementary, with complex omics testing centralized and high-frequency biomarkers moving closer to the point of care.
By 2035, leading companies are likely to own deeper data relationships with veterinary practices. Diagnostic data can inform treatment pathways, population health, quality standards and research. The competitive advantage will shift toward companies that combine instrument installed base, lab network scale, proprietary biomarkers, software integration and high clinical confidence. Smaller companies can still create value through specialized molecular tests, oncology, microbiome, genetics, AI or region-specific distribution partnerships.
Pet Biomarkers Market Buyer Decision-Making Criteria
Veterinary clinics and laboratories prioritize clinical validity, reproducibility, sensitivity, specificity, reference intervals, sample stability, turnaround time and whether the result changes a treatment decision. Buyers also assess instrument compatibility, cost per test, repeat-testing frequency, interpretation support and integration with practice software. For newer oncology and genomic biomarkers, peer-reviewed evidence and specialist acceptance are especially important.
For specialty diagnostics, buyers assess clinical validation, interpretability, sensitivity and specificity, fit with treatment decisions and owner willingness to pay. In emerging markets, distributors and local service networks are particularly important because instrument uptime and reagent availability can be stronger purchase determinants than brand alone.
Pet Biomarkers Market Economic & Investment Analysis
The pet biomarkers market benefits from recurring revenue because chronic kidney, cardiac, endocrine and oncology patients require repeated testing over time. Attractive assets combine high clinical utility with repeatable testing and scalable reference-lab or point-of-care workflows. Investment is strongest in biomarker platforms that can expand into multiple disease areas, generate proprietary datasets and support therapeutic development or companion diagnostics.
Risk is concentrated in veterinary visit softness, pricing pressure, clinic consolidation and high research costs for new assays. Companies that rely on premium tests may experience greater sensitivity when pet owners defer care. Conversely, diagnostic tools that improve clinic productivity or enable earlier intervention can remain resilient because they support medical decision-making and practice economics. M&A is likely to remain active around specialty testing, software, AI, imaging and regional reference-lab capacity.
Pet Biomarkers Investment Trends in the Market
- Capital is moving toward AI-enabled image and cytology interpretation that can reduce dependence on scarce specialists.
- Diagnostic leaders continue to invest in broader recurring test menus around existing analyzer platforms.
- Cancer and chronic-disease diagnostics are attracting investment as pets live longer and care standards rise.
- Reference laboratory capacity and logistics networks remain important because specialty tests cannot all be economically performed in-clinic.
- Software integration and cloud connectivity are becoming part of diagnostic-platform investment rather than a separate IT layer.
- Emerging-market expansion increasingly uses distributor partnerships and regional hospital chains to accelerate analyzer placements.
Strategic Indicators For Pet Biomarkers Market
High Regulation Impact
Biomarker assays must meet veterinary diagnostic quality, labeling and laboratory requirements that differ by region. Emerging genomic and oncology tests also require strong analytical validation, reproducible cutoffs and transparent clinical-performance evidence. Regulation is less centralized than in human IVDs, but buyer expectations are rising as high-value tests influence treatment decisions.
High Investment Activity
Investment is increasing in oncology liquid biopsy, proteomics, genomics, renal biomarkers and AI-enabled interpretation. Capital favors platforms that can convert discovery into validated tests, access large clinical sample sets and distribute through established veterinary laboratory networks.
Supply Chain Disruption
Biomarker testing depends on antibodies, enzymes, reference materials, microfluidic cartridges, sequencing reagents and cold-chain logistics. Shortages can interrupt assay availability and delay validation studies, increasing the value of qualified second sources and platform standardization.
Pricing Volatility
Routine protein biomarkers generally support moderate recurring pricing, while genomic, proteomic and oncology panels command higher prices because of laboratory complexity and interpretation. Price sensitivity is greatest in uninsured markets and for screening tests without clear treatment consequences.
Procurement Pressure
Veterinary groups increasingly evaluate biomarker tests within broader diagnostic contracts covering analyzers, laboratory services and software. Vendors with integrated ecosystems can bundle testing, but independent biomarker companies can compete through superior clinical utility and specialty expertise.
New Technology Adoption
NGS, digital PCR, mass spectrometry, multiplex immunoassays, microfluidics and AI are expanding the range of measurable veterinary biomarkers. Adoption depends on reducing sample volume, turnaround time and cost while preserving analytical quality.
Regional Expansion Opportunity
North America leads specialty biomarker adoption, while Europe has strong academic and laboratory networks. Asia-Pacific offers the fastest expansion potential as urban companion-animal care, specialty hospitals and molecular testing capacity grow.
Government Policy Support
Public support is indirect and comes through veterinary research funding, animal-health surveillance, university laboratories and broader genomics infrastructure. Policy is most influential where it improves laboratory capacity, research collaboration and cross-border movement of biological samples.
Pricing Intelligence
Routine biomarker assays are typically priced as add-ons to chemistry or immunoassay panels, while specialty oncology, genomic and proteomic tests carry premium pricing. Commercial success depends on linking price to decision value, repeat-testing frequency and avoided downstream diagnostic work.
Disruption Analysis of Pet Biomarkers Market
AI-enabled diagnostics are disrupting traditional specialist-dependent workflows by making cytology, radiology triage and image interpretation faster and more scalable. The technology does not eliminate specialist review for complex cases, but it can change which cases are escalated and how quickly preliminary answers are available. This is particularly relevant for general-practice clinics where access to boarded specialists is limited.
At the same time, reference laboratories are being challenged by expanding point-of-care menus. The likely outcome is a hybrid model: routine chemistry, hematology, urinalysis and selected cytology move in-clinic, while advanced molecular, oncology, pathology and complex infectious-disease testing remain centralized. Vendors that participate in both settings can optimize where each test is performed rather than compete on one modality alone.
Pet Biomarkers Market BCG Matrix: Company Evaluation
STAR
IDEXX Laboratories is positioned as a Star because of its large installed base, recurring Companion Animal Group diagnostics revenue, reference-lab network and broad innovation pipeline across in-clinic analyzers, fecal testing, kidney biomarkers, cancer diagnostics and digital workflow. Zoetis is also strategically strong through its VETSCAN platform and broad animal-health commercial reach, although diagnostics is a smaller share of total company revenue.
POTENTIAL
Neogen, QIAGEN, Thermo Fisher Scientific, bioMérieux, Boehringer Ingelheim Animal Health, VIMIAN/INDICAL and specialist diagnostic companies represent Potential players across molecular testing, sample preparation, microbiology, animal genetics and specialty workflows. Their competitive upside depends on veterinary-specific menu development, distribution access and integration into high-frequency clinic workflows.
Pet Biomarkers Market Dynamics
Driver Impact Analysis
| Driver | Market Growth Impact | Demand Concentration | Impacted Use Case | Strategic Impact |
| Earlier disease detection and precision care | High | North America, Europe, urban Asia-Pacific | Renal, cardiac, oncology and endocrine screening | Increases use of biomarkers before overt clinical disease and supports repeat testing. |
| Aging pet population and chronic disease burden | High | Dogs and cats | Kidney disease, cancer, cardiac and metabolic disorders | Expands addressable testing population and longitudinal monitoring. |
| Multi-omics and AI-enabled discovery | Medium-High | Specialty labs and research centers | Composite panels and novel biomarker development | Accelerates discovery and supports higher-value differentiated panels. |
| Reference-lab and point-of-care menu expansion | Medium-High | Global veterinary clinics | Routine and specialty biomarker testing | Broadens access and embeds biomarker testing in everyday workflows. |
Driver: Earlier Disease Detection and Precision Companion-Animal Care
Demand for pet biomarkers is rising as veterinary care shifts toward earlier intervention and longitudinal management. Biomarkers can identify organ dysfunction before overt clinical deterioration, stratify risk, support specialist referral and monitor response. The strongest growth occurs where markers are embedded in routine workflows and supported by clear clinical thresholds.
Restraint Impact Analysis
| Restraint | Drag on Market Growth | Primary Impact Area | Impacted Use Case | Strategic Impact |
| Limited clinical validation and standardization | High | Emerging biomarkers | Oncology, multi-omics and specialty panels | Slows clinician adoption until prospective evidence and reference intervals are established. |
| Pet-owner affordability | High | Premium testing | Genomic and oncology screening | Reduces uptake where tests are discretionary or not linked to immediate treatment. |
| Sample and pre-analytical variability | Medium | Assay performance | Blood, urine, tissue and multi-omics testing | Requires strict collection, transport and quality-control protocols. |
| Uneven specialty-lab access | Medium | Regional expansion | High-complexity biomarker testing | Favors centralized laboratories and distributor-supported sample logistics. |
Restraint: Clinical Validation, Standardization and Test Affordability
Many emerging veterinary biomarkers have promising discovery data but limited prospective validation across breeds, ages and comorbidities. Small study populations, inconsistent reference intervals and uncertain treatment consequences can slow adoption. High-cost molecular and multi-omics tests also face owner affordability constraints, especially when insurance coverage is limited.
Pet Biomarkers Market Segment Analysis
The global Pet Biomarkers market is segmented based on Biomarker Type, Detection Technology, Animal Type, Disease Area, Sample Type, Application, End User, distribution channel, and region.
By Biomarker Type
Protein Biomarkers Will Remain the Largest Commercial Category
Protein markers are the most established veterinary biomarker class because immunoassay and chemistry workflows are already embedded in clinics and reference laboratories. Renal, cardiac, inflammatory and endocrine proteins support repeated testing and have clear clinical interpretation. Genetic and multi-omics biomarkers will grow faster from a smaller base as sequencing costs decline and disease-specific validation improves.
By Detection Technology
Immunoassay Will Lead, While Molecular and Proteomic Platforms Grow Fastest
Immunoassays lead because they combine sensitivity, relatively low cost and compatibility with point-of-care and reference-lab workflows. PCR and NGS are gaining share in oncology and inherited disease, while mass spectrometry and proteomics are important for discovery and high-complexity panels. Digital interpretation increasingly connects these modalities into composite risk scores.
By Animal Type
Dogs Will Continue to Account for the Largest Share
Dogs account for the largest diagnostic opportunity because of high veterinary utilization, broad disease-screening protocols and large spending on chronic disease and specialty care. Cats are a strong growth segment because feline medicine is increasing its focus on early kidney disease, endocrine disorders and preventive diagnostics. Horses and other companion animals remain more specialized and geographically concentrated.
By Disease Area
Wellness Screening Leads; Oncology Testing Gains Strategic Importance
Routine wellness and preventive screening generates the broadest test volume because it spans healthy animals, aging pets and pre-surgical assessment. Oncology testing is becoming strategically important as diagnostic developers introduce tumor-specific panels, cytology automation and molecular assays. Renal testing remains another high-value area because chronic kidney disease is common in older dogs and cats.
By Sample Type
Blood and Serum/Plasma Will Remain Dominant
Blood, serum and plasma dominate because they support chemistry, hematology, endocrine, infectious disease and many specialty tests. Urine is important for renal and urinary disease, while fecal samples are gaining value through antigen-based parasite detection. Tissue and cytology samples should grow with digital pathology and oncology diagnostics.
By Application
Disease Diagnosis Will Remain the Largest Application
Disease diagnosis remains the largest application, but health screening and treatment monitoring are becoming more important as preventive medicine and chronic disease management expand. Connected analyzers can support serial monitoring and trend analysis, creating more consistent diagnostic utilization across the patient lifecycle.
By End User
Veterinary Hospitals and Clinics Control Most Testing Decisions
Veterinary hospitals and clinics remain the primary end users and control whether tests are performed in-clinic or sent to a reference laboratory. Corporate clinic groups are increasingly important because they standardize protocols and vendor contracts. Reference labs remain essential for complex pathology, molecular and specialty tests.
By Distribution Channel
Direct Sales and Integrated Lab Relationships Remain Critical
Direct sales is important for instrument placements and large hospital groups because vendors must support training, installation and service. Veterinary distributors extend reach to smaller practices and emerging markets. Reference-lab networks operate as both service providers and channels for consumables, logistics and specialist interpretation.
Pet Biomarkers Market Geographical Penetration
U.S. Pet Biomarkers Market Landscape
The U.S. is the largest national pet biomarkers market because companion-animal healthcare spending, specialty hospitals, reference laboratories and advanced testing adoption are high. IDEXX, Zoetis and major veterinary hospital networks support rapid commercialization of renal, cardiac, endocrine and oncology biomarkers. Growth is increasingly tied to cancer testing, AI-supported interpretation and longitudinal disease monitoring.
Germany Pet Biomarkers Market Outlook
Germany has a mature veterinary market with strong diagnostic adoption, laboratory infrastructure and high standards of companion-animal care. Growth opportunities include molecular testing, advanced imaging, point-of-care analyzers and integrated lab services.
Japan Pet Biomarkers Market Trends
Japan combines an aging pet population with sophisticated veterinary care and strong demand for chronic disease diagnostics. Compact analyzers, imaging, renal testing and specialty services are particularly relevant.
China Pet Biomarkers Market Outlook
China is one of the fastest-growing opportunities as pet ownership, premium veterinary hospitals and urban pet spending expand. The market remains fragmented, creating opportunity for instrument vendors, regional reference labs and domestic diagnostic manufacturers.
Brazil Pet Biomarkers Market Outlook
Brazil has a large companion-animal population and expanding veterinary services. Market growth is supported by urban pet spending, distributor networks and rising adoption of in-clinic analyzers, although affordability and import costs remain constraints.
Middle East and Africa Pet Biomarkers Market Outlook
The Gulf states, South Africa and selected urban markets provide the strongest opportunities. Premium veterinary hospitals can support advanced testing, while broader regional adoption depends on distributor service, reagent availability and local purchasing power.
Pet Biomarkers Market Competitive Landscape
- IDEXX Laboratories holds the strongest commercial position through routine and specialty veterinary diagnostics, including SDMA and expanding cancer-related testing.
- Zoetis participates through VETSCAN and broader companion-animal clinical relationships, creating opportunities to integrate biomarkers with therapeutic franchises.
- Reference-laboratory groups and molecular specialists compete by expanding assay menus, validation datasets and specialist interpretation.
- Thermo Fisher Scientific, QIAGEN and Bio-Rad provide enabling platforms in PCR, sequencing, proteomics, immunoassay and laboratory instrumentation that support biomarker discovery and testing.
- Competition is shifting from single-analyte ownership toward proprietary panels, longitudinal data, AI interpretation and workflow integration.
- Partnerships with veterinary oncology, cardiology, nephrology and pharmaceutical developers are increasingly important for establishing clinical utility and companion-diagnostic roles.
Public Company Q1-Q2 2026 Performance Comparison
| Public Company | Q1-Q2 2026 Performance | Pet Biomarker Exposure | Factors Driving Growth |
| IDEXX Laboratories | Q1 2026 results were reported in May; Q2 2026 results and investor update were scheduled/reported in early August. Management highlighted CAG Diagnostics, inVue Dx, Cancer Dx and continued SDMA expansion. | Highest direct exposure among public companies; biomarker testing is embedded across chemistry, renal, endocrine, infectious-disease and emerging cancer workflows. | Recurring test utilization, SDMA integration, cancer testing, analyzer placements, reference-lab growth and AI-supported interpretation. |
| Zoetis | Q1 2026 revenue was about US$2.3 billion, up 3% reported; Q2 2026 corporate performance was scheduled for August 6. Companion-animal demand remains the key strategic base. | Biomarker exposure through VETSCAN diagnostics and therapeutic-development adjacencies; smaller than pharmaceutical and vaccine revenue. | VETSCAN adoption, companion-animal relationships, cross-selling with therapeutics and potential companion-diagnostic use. |
| Thermo Fisher Scientific | Q2 2026 revenue grew 10% to US$11.99 billion, with 5% organic growth. | Indirect but strategically important through proteomics, mass spectrometry, molecular biology, antibodies and laboratory infrastructure used in biomarker discovery and testing. | Stronger life-science demand, Olink proteomics, Orbitrap platforms, molecular tools and translational research spending. |
| QIAGEN | Q2 2026 results were scheduled for August 5; the company continued expanding molecular and syndromic testing capabilities during 2026. | Indirect-to-moderate exposure through PCR, sample preparation and genomic workflows applicable to veterinary biomarker development. | PCR and sample-prep installed base, molecular assay development, genomics workflow expansion and research-to-clinical translation. |
| Bio-Rad Laboratories | Q1 2026 sales were US$592.1 million, up 1.1% reported, while currency-neutral sales declined 4.2%. Q2 results were scheduled for August 4. | Indirect exposure through immunoassay, digital PCR, quality-control and life-science technologies used in biomarker discovery and assay validation. | Clinical diagnostics installed base, digital PCR, immunoassay capabilities, quality controls and recovery in research demand. |
Market Ecosystem Table
| Value Chain Sector | Representative Companies | Role in Pet Biomarkers Ecosystem |
| Biomarker discovery & omics platforms | Thermo Fisher Scientific, QIAGEN, Bio-Rad, Olink/Thermo Fisher, academic genomics and proteomics centers | Identify and validate protein, genetic, metabolic and multi-omics biomarkers. |
| Veterinary diagnostic platform leaders | IDEXX Laboratories, Zoetis/VETSCAN, Antech Diagnostics, Fujifilm Veterinary Systems | Commercialize assays, instruments and integrated veterinary testing workflows. |
| Reference laboratories | IDEXX Reference Laboratories, Antech Diagnostics, regional veterinary specialty laboratories | Run complex biomarker assays, maintain reference datasets and provide specialist interpretation. |
| Oncology & specialty biomarker developers | PetDx / Antech Oncology Diagnostics, Volition Veterinary Diagnostics, specialty veterinary oncology labs | Develop cancer detection, recurrence, immune and other disease-specific biomarkers. |
| Molecular & sample-prep suppliers | QIAGEN, Thermo Fisher Scientific, Bio-Rad, INDICAL/VIMIAN | Provide extraction, PCR, dPCR, sequencing and molecular assay infrastructure. |
| Antibodies, reagents & assay components | Bio-Rad, Thermo Fisher, specialty antibody and enzyme suppliers | Supply antibodies, standards, enzymes, controls and assay-development materials. |
| Veterinary pharmaceutical partners | Zoetis, Boehringer Ingelheim Animal Health, Elanco, Virbac | Use biomarkers for clinical development, treatment stratification and potential companion diagnostics. |
| Veterinary hospitals & specialists | Mars Veterinary Health, NVA/Ethos, university hospitals, independent specialty centers | Order, interpret and longitudinally monitor biomarker tests in clinical care. |
| Software & AI interpretation | IDEXX software, veterinary AI startups, practice-management platforms | Integrate biomarker results with longitudinal records and clinical decision support. |
| Distribution & logistics | Covetrus, Patterson Veterinary, regional distributors, lab courier networks | Support test-kit distribution, instrument service and biological sample logistics. |
Key Companies of Pet Biomarkers Market
- IDEXX Laboratories
- Zoetis
- Antech Diagnostics (Mars Petcare)
- PetDx / Antech Oncology Diagnostics
- Bio-Rad Laboratories
- Thermo Fisher Scientific
- QIAGEN
- bioMérieux
- VIMIAN / INDICAL Bioscience
- Boehringer Ingelheim Animal Health
- Fujifilm Veterinary Systems
- Antech Diagnostics
- Volition Veterinary Diagnostics
- Antech Diagnostics
- Boehringer Ingelheim Animal Health
Company Profiles
IDEXX Laboratories
IDEXX is the global leader in companion-animal diagnostics, with a model built around in-clinic analyzers, recurring consumables, reference laboratories, software and a large installed base. Its strategic priorities include increasing diagnostic utilization per clinic, expanding inVue Dx capabilities, growing cancer and fecal testing, integrating SDMA more broadly and deepening software connectivity.
Zoetis
Zoetis participates through VETSCAN analyzers and diagnostic products supported by its global animal-health commercial organization. Diagnostics complements the company’s pharmaceutical and vaccine portfolio and can strengthen clinic relationships. Growth depends on analyzer placements, menu breadth, service and the ability to cross-sell within companion-animal accounts.
Antech Diagnostics (Mars Petcare)
Antech operates one of the largest veterinary reference-laboratory networks and benefits from integration with Mars Veterinary Health. Its capabilities span pathology, imaging, molecular testing and specialty diagnostics. Vertical proximity to large hospital networks provides data, workflow and customer-access advantages.
PetDx / Antech Oncology Diagnostics
Heska is now part of Mars Petcare and contributes in-clinic diagnostic analyzers, imaging and point-of-care capabilities. Integration with Antech and Mars veterinary hospitals can create a broader clinic-to-reference-lab diagnostic platform.
Bio-Rad Laboratories
Neogen has animal safety, pet health and diagnostic capabilities, including infectious-disease, genomics and animal-health products. Its near-term performance has been affected by portfolio and supply-chain issues, but its global animal-health reach remains strategically relevant.
Thermo Fisher Scientific
Thermo Fisher provides molecular, laboratory and research technologies that support veterinary diagnostics, including PCR, mass spectrometry, reagents and sample-preparation workflows. Its role is strongest as an enabling platform supplier rather than a dedicated pet-diagnostics vendor.
Pet Biomarkers Market Major Pain Points
- Limited prospective validation for many emerging biomarkers across breeds and clinical settings.
- Difficulty establishing species-specific reference intervals and clinically meaningful cutoffs.
- High cost of oncology, genomic and multi-omics tests relative to routine veterinary diagnostics.
- Uneven access to specialty laboratories and veterinary specialists outside major urban markets.
- Small sample volumes and pre-analytical variability can affect assay performance.
- Uncertain treatment consequences can limit willingness to pay for screening biomarkers.
- Need for interoperability between biomarker results, practice software and longitudinal patient records.
- Data interoperability gaps between analyzers, labs and practice-management systems.
Pet Biomarkers Market Recent Developments
- May 2026: IDEXX announced broader integration of SDMA into common Catalyst chemistry profiles, increasing routine access to an established kidney biomarker.
- May 2026: IDEXX expanded its Fecal Dx antigen testing menu, reinforcing the trend toward biomarker-based disease detection within routine companion-animal workflows.
- 2026: IDEXX continued development and rollout planning for cancer diagnostics and AI-enabled inVue Dx applications, supporting expansion into oncology and cytology-related biomarker interpretation.
- 2026: Veterinary oncology developers and reference laboratories continued expanding molecular and liquid-biopsy testing strategies for canine cancer detection and monitoring.
- 2026: Broader adoption of proteomic, genomic and AI platforms across life sciences continued to reduce technical barriers for veterinary biomarker discovery and translation.
Analyst View / Opinion on Pet Biomarkers Market
- Pet biomarkers are becoming a distinct high-value layer within veterinary diagnostics because they can move care from symptom-driven testing toward earlier and more predictive intervention.
- Renal biomarkers provide the strongest current commercial proof point, while oncology represents the largest white-space opportunity for premium growth.
- The most defensible companies will combine proprietary biomarkers with large clinical datasets, reference-lab reach and workflow integration rather than compete on assay chemistry alone.
- Multi-omics and AI will broaden discovery, but commercial adoption will remain evidence-driven and dependent on reproducible clinical utility.
- Public diagnostic and life-science companies can participate through enabling platforms even when they do not disclose pet-biomarker revenue separately.
- Long-term leadership will depend on validated disease-specific panels, repeat testing, clinician trust and the ability to link biomarker results to treatment decisions.
Pet Biomarkers Market Target Audience
| Industry | Who Should Buy This Report? | Reason to Buy This Report |
| Veterinary Diagnostics | Assay developers, instrument OEMs, reference laboratories | Assess biomarker adoption, validation requirements and recurring testing opportunities. |
| Animal Health | Pharma, vaccine and pet-health companies | Identify companion-diagnostic opportunities and biomarkers for clinical development. |
| Veterinary Providers | Hospital groups, specialists and clinical pathologists | Benchmark biomarker workflows, clinical utility and investment priorities. |
| Genomics & Proteomics | Sequencing, PCR, proteomics and sample-prep companies | Evaluate veterinary translation opportunities for advanced molecular platforms. |
| Oncology & Specialty Care | Cancer-test developers, specialty hospitals and researchers | Assess liquid biopsy, molecular oncology and longitudinal monitoring opportunities. |
| Distribution | Veterinary distributors and sample-logistics providers | Understand assay demand, regional access gaps and service requirements. |
| Investors & Consulting | PE, VC, institutional investors and strategy teams | Evaluate growth, competitive positioning, licensing and M&A opportunities. |
Why Choose DATAM?
- Data-driven insights combining market sizing, installed-base analysis, recurring consumables, reference-lab economics and country-level opportunity.
- Post-purchase analyst consultations for market entry, product strategy, partnerships and custom segmentation.
- Annual updates covering product launches, company performance, diagnostic innovation and competitive developments.
- Specialized focus on emerging veterinary markets instead of generalized healthcare analysis.
- Actionable analysis connecting technology trends with clinic economics, pet-owner behavior and distribution requirements.
What DATAM Uniquely Provides
- Ten-year forecasts across product type, technology, animal type, test type, sample type, application, end user, distribution channel and region.
- A market ecosystem view linking reagent suppliers, analyzer OEMs, reference labs, software, hospital groups and distributors.
- Public-company performance comparison tied specifically to pet-diagnostics exposure.
- Buyer-focused analysis of analyzer economics, recurring consumables, turnaround time and workflow integration.
- Country-level views linking pet ownership, veterinary infrastructure, affordability and diagnostic penetration.
